tolvaptan has been researched along with Neoplasms in 14 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 8 (57.14) | 24.3611 |
| 2020's | 6 (42.86) | 2.80 |
| Authors | Studies |
|---|---|
| Huigens, RW; Luesch, H; Norwood, VM; Paciaroni, NG; Ratnayake, R | 1 |
| Kawada, T | 1 |
| Anceschi, C; Baldanzi, F; Fibbi, B; Maggi, M; Marroncini, G; Naldi, L; Peri, A | 1 |
| Jhaveri, KD; Rondon-Berrios, H; Workeneh, BT | 1 |
| Basal, FB; Bilgetekin, I; Demirci, U; Erturk, I; Karacin, C; Karadurmus, N; Oksuzoglu, B | 1 |
| Al-Othman, S; Blackhall, F; Brabant, G; Chatzimavridou-Grigoriadou, V; Higham, CE; King, J; Kyriacou, A; Trainer, PJ | 1 |
| Antonuzzo, A; Berardi, R; Blasi, L; Buosi, R; Lorusso, V; Migliorino, MR; Montesarchio, V; Peri, A; Sabbatini, R; Zilembo, N | 1 |
| Kitchlu, A; Rosner, MH | 1 |
| Ali, N; George, M; Lahoti, A; Palla, S; Salahudeen, AK | 1 |
| Akiyama, T; Aoki, Y; Hosokawa, I; Kato, A; Kawamoto, J; Kuboki, S; Mitsuhashi, N; Miyazaki, M; Nemoto, S; Nishino, H; Ohtsuka, M; Sasaki, K; Satoh, Y; Shimazaki, R; Shimizu, H; Shimizu, Y; Teranaka, R; Ueda, A; Yoichi, T; Yoshitomi, H | 1 |
| Ahmad, F; Blais, JD; Chiodo, J; Czerwiec, FS; Glaser, LA; Gralla, RJ; Zhou, W | 1 |
| Villabona, C | 1 |
| Caimi, G; Urso, C | 1 |
| Castillo, JJ; Justice, E; Vincent, M | 1 |
6 review(s) available for tolvaptan and Neoplasms
| Article | Year |
|---|---|
Hyponatremia in the cancer patient.
Topics: Antidiuretic Hormone Receptor Antagonists; Benzazepines; Humans; Hyponatremia; Inappropriate ADH Syndrome; Neoplasms; Quality of Life; Tolvaptan | 2020 |
Practical issues for the management of hyponatremia in oncology.
Topics: Antidiuretic Hormone Receptor Antagonists; Disease Management; Humans; Hyponatremia; Inappropriate ADH Syndrome; Neoplasms; Tolvaptan | 2018 |
Hyponatremia in patients with cancer.
Topics: Fluid Therapy; Humans; Hyponatremia; Inappropriate ADH Syndrome; Neoplasms; Tolvaptan | 2019 |
[Vasopressin receptor antagonists: the vaptans].
Topics: Adult; Antidiuretic Hormone Receptor Antagonists; Aquaporin 2; Benzamides; Benzazepines; Calcium Signaling; Clinical Trials as Topic; Cyclic AMP; Double-Blind Method; Drug Therapy, Combination; Heart Failure; Humans; Hyponatremia; Inappropriate ADH Syndrome; Kidney Tubules, Collecting; Liver Cirrhosis; Morpholines; Multicenter Studies as Topic; Neoplasms; Pituitary Gland, Anterior; Pyrroles; Randomized Controlled Trials as Topic; Receptors, Vasopressin; Second Messenger Systems; Spiro Compounds; Tolvaptan; Vasopressins | 2010 |
[Hyponatremic syndrome].
Topics: Aging; Antidiuretic Hormone Receptor Antagonists; Arginine Vasopressin; Benzazepines; Brain; Brain Edema; Exercise; Humans; Hyponatremia; Inappropriate ADH Syndrome; Infections; Inflammation; Kidney; Natriuresis; Neoplasms; Osmotic Pressure; Renal Replacement Therapy; Sodium; Tolvaptan; Water Intoxication | 2012 |
Diagnosis and management of hyponatremia in cancer patients.
Topics: Antidiuretic Hormone Receptor Antagonists; Arginine Vasopressin; Benzazepines; Disease Management; Humans; Hyponatremia; Hypovolemia; Inappropriate ADH Syndrome; Neoplasms; Receptors, Vasopressin; Risk Factors; Sodium; Tolvaptan | 2012 |
2 trial(s) available for tolvaptan and Neoplasms
| Article | Year |
|---|---|
Tolvaptan in hospitalized cancer patients with hyponatremia: a double-blind, randomized, placebo-controlled clinical trial on efficacy and safety.
Topics: Adult; Aged; Aged, 80 and over; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Female; Humans; Hyponatremia; Male; Medication Adherence; Middle Aged; Neoplasms; Sodium; Time Factors; Tolvaptan; Treatment Outcome | 2014 |
Tolvaptan use in cancer patients with hyponatremia due to the syndrome of inappropriate antidiuretic hormone: a post hoc analysis of the SALT-1 and SALT-2 trials.
Topics: Administration, Oral; Aged; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Double-Blind Method; Female; Humans; Hyponatremia; Inappropriate ADH Syndrome; Male; Middle Aged; Neoplasms; Sodium; Tolvaptan; Treatment Outcome | 2017 |
6 other study(ies) available for tolvaptan and Neoplasms
| Article | Year |
|---|---|
Yohimbine as a Starting Point to Access Diverse Natural Product-Like Agents with Re-programmed Activities against Cancer-Relevant GPCR Targets.
Topics: Antineoplastic Agents; Biological Products; Dose-Response Relationship, Drug; Humans; Molecular Structure; Molecular Targeted Therapy; Neoplasms; Receptors, G-Protein-Coupled; Structure-Activity Relationship; Yohimbine | 2020 |
Survival analysis in cancer patients with hyponatremia: effectiveness of tolvaptan treatment.
Topics: Antidiuretic Hormone Receptor Antagonists; Humans; Hyponatremia; Neoplasms; Survival Analysis; Tolvaptan; Treatment Outcome | 2022 |
The V
Topics: Antidiuretic Hormone Receptor Antagonists; Benzazepines; Cell Proliferation; Humans; Hyponatremia; Neoplasms; rho-Associated Kinases; Sodium; Tolvaptan | 2022 |
Tolvaptan treatment in hyponatremia due to the syndrome of inappropriate secretion of antidiuretic hormone (SIADH): effects on survival in patients with cancer.
Topics: Adult; Aged; Aged, 80 and over; Antidiuretic Hormone Receptor Antagonists; Female; Humans; Hyponatremia; Inappropriate ADH Syndrome; Male; Middle Aged; Neoplasms; Retrospective Studies; Survival Rate; Tolvaptan | 2021 |
Clinical Experience of the Efficacy and Safety of Low-dose Tolvaptan Therapy in a UK Tertiary Oncology Setting.
Topics: Aged; Antidiuretic Hormone Receptor Antagonists; Female; Follow-Up Studies; Humans; Hyponatremia; Male; Neoplasms; Prognosis; Retrospective Studies; Tolvaptan | 2021 |
[Effect of tolvaptan on ascites due to malignancy].
Topics: Aged; Aged, 80 and over; Antidiuretic Hormone Receptor Antagonists; Ascites; Benzazepines; Female; Humans; Male; Middle Aged; Neoplasms; Tolvaptan | 2015 |